Profile Response Detail

Molecular Profile SMO D473G
Therapy Vismodegib
Indication/Tumor Type Advanced Solid Tumor
Response Type resistant
Create By tyin
Update By driscd

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMO D473G Advanced Solid Tumor resistant Vismodegib Preclinical - Cell culture Actionable In a preclinical study, mouse fibroblast cells expressing human SMO D473G were resistant to Hedgehog pathway inhibition by Erivedge (vismodegib) in culture (PMID: 25801792). 25801792
SMO D473G Advanced Solid Tumor resistant Vismodegib Preclinical Actionable In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D477G (corresponding to human SMO D473G) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493). 26823493
PubMed Id Reference Title Details
(26823493) Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma. Full reference...
(25801792) Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. Full reference...